Armed Antibodies™

Viventia’s Armed Antibodies™ represent a new generation of monoclonal antibody-based drugs that combine power and precision to overcome cancers. We call our cancer fighting drugs Armed Antibodies™ because they consist of two components: powerful cytotoxic protein prodrugs combined with highly precise antibody fragments that target only cancer cells. We believe that this approach has the potential to yield safer and more beneficial therapies than existing cancer drugs.

While there have already been several clinically and commercially successful monoclonal antibody therapies for cancer, we believe Viventia has the potential to be an industry leader in the field of cancer-killing payload delivery. Given a global market for cancer therapeutics that already exceeds US $20 billion, the market potential of our Armed Antibodies™ is substantial.


Copyright 2007 © Viventia Biotech Inc. All rights reserved.
The content of this site is for informational purposes only and is not intended to replace the advice of a health care professional.
Please consult your doctor if you have any questions regarding the information contained in this site.